Приказ основних података о документу
N-terminal pro-b-type natriuretic peptide in patients with hypertensive heart disease
dc.creator | Pejović, Janko | |
dc.creator | Ignjatović, Svetlana | |
dc.creator | Dajak, Marijana | |
dc.creator | Majkić-Singh, Nada | |
dc.creator | Vučinić, Žarko | |
dc.date.accessioned | 2019-09-02T11:25:22Z | |
dc.date.available | 2019-09-02T11:25:22Z | |
dc.date.issued | 2011 | |
dc.identifier.issn | 1452-8258 | |
dc.identifier.uri | https://farfar.pharmacy.bg.ac.rs/handle/123456789/1557 | |
dc.description.abstract | Patients with hypertensive heart disease have elevated concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP). The aim of our study was to evaluate NT-proBNP in patients with long-standing hypertension and in patients with signs of hypertensive cardiomyopathy. The study included three groups of 50 subjects: healthy persons (Control Group), patients with hypertension and normal left ventricular systolic function (Group 1) and patients with long-standing hypertension and signs of hypertensive cardiomyopathy with impaired left ventricular systolic function (Group 2). Our results show a very good correlation (Pearson's test) between NT-proBNP in Group 1 and Group 2 and C-reactive protein (Group 1: r = 0.8424; Group 2: r = 0.6650), systolic blood pressure (Group 1: r = 0.7213; Group 2: r = 0.4856), diastolic blood pressure (Group 1: r = 0.4282; Group 2: r = 0.3989) and ejection fraction (Group 1: r = -0.7390; Group 2: r = 0.9111). ROC analysis revealed that the AUC between the Control Group and Group 1 for NT-proBNP (0.912) was not significantly different (p>0.05) from the AUC for systolic (0.924) and diastolic pressure (0.937). A cut-off value for NT-proBNP of 5.89 pmol/L can be used to reliably distinguish patients of Group 1 from the Control Group, and a cut-off value of 21.67 pmol/L reliably separates patients from Group 1 and Group 2 (in both cases, the AUC is 1.000). Patients in Group 2 who belonged to the II and III New York Heart Association (NYHA) class had significantly higher levels of NT-proBNP than those in NYHA class I (ANOVA test, p=0.001). These data suggest that NT-proBNP is a useful biomarker for distinguishing patients with long-standing hypertension who are at risk of heart failure, allowing optimization and proper treatment of these patients. | en |
dc.publisher | Društvo medicinskih biohemičara Srbije, Beograd i Versita | |
dc.relation | info:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/175036/RS// | |
dc.rights | openAccess | |
dc.source | Journal of Medical Biochemistry | |
dc.subject | N-terminal pro-B-type natriuretic peptide | en |
dc.subject | hypertensive heart disease | en |
dc.subject | hypertensive cardiomyopathy | en |
dc.title | N-terminal pro-b-type natriuretic peptide in patients with hypertensive heart disease | en |
dc.type | article | |
dc.rights.license | ARR | |
dcterms.abstract | Игњатовић, Светлана; Пејовић, Јанко; Мајкић-Сингх, Нада; Дајак, Маријана; Вучинић, Жарко; | |
dc.citation.volume | 30 | |
dc.citation.issue | 3 | |
dc.citation.spage | 244 | |
dc.citation.epage | 249 | |
dc.citation.other | 30(3): 244-249 | |
dc.citation.rank | M23 | |
dc.identifier.wos | 000292419300010 | |
dc.identifier.doi | 10.2478/v10011-011-0016-4 | |
dc.identifier.scopus | 2-s2.0-79959535160 | |
dc.identifier.fulltext | https://farfar.pharmacy.bg.ac.rs//bitstream/id/409/1555.pdf | |
dc.type.version | publishedVersion |